Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Proteolysis-targeting chimeras (PROTAC) | 2 |
Oncolytic virus | 1 |
Chemical drugs | 1 |
Target |
Mechanism PKR inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EIF2AK4 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HIF-PHs inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CCT-137690 ( AURK x FLT3 ) | Acute Myeloid Leukemia More | Preclinical |
IOX5 ( HIF-PHs ) | Acute Myeloid Leukemia More | Preclinical |
NXP-800 ( EIF2AK4 ) | Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma More | Preclinical |
CCT374705 ( BCL6 ) | Lymphoma More | Preclinical |
CCT251455 ( TTK ) | Neoplasms More | Preclinical |